Fluicell publishes report for the third quarter 2022
Today, November 30 2022, Fluicell publishes the interim report for the period July 1 to September 30, 2022. The full report can be accessed through Fluicell’s investor relations page using or using the link provided below.
CEO Victoire Viannay comments:
“During the first nine months of 2022, Fluicell has taken important steps on its journey to develop from a company solely focused on research technology to an innovation-driven life science company with operations in the business areas — life sciences tools and applications, human tissue-based therapies and human tissue-based in vitro technology for drug development and research. These three areas are all sectors that make up fast-growing markets where Fluicell’s technology and expertise have the potential to bring significant advances in research and healthcare.
In summary, Fluicell is well positioned to take the next step in the company’s development. Over the past two years, we have taken great steps towards becoming a versatile life science company with a unique and innovative product range. Fluicell has the ability and technology to meet customer needs in research and drug development. We are now aiming to achieve significant sales growth for our market-leading research products while achieving a rapid entry into the emerging markets for in vitro technology and regenerative medicine.”
July – September 2022 in summary
- Operating income amounted to KSEK 3 415 (1 436)
- Net sales of KSEK 512 (1 062)
- Operating profit before depreciation, EBITDA, amounted to KSEK -2 609 (-4 572)
January – September 2022 in summary
- Operating income amounted to KSEK 5 398 (3 094)
- Net sales of KSEK 1 842 (2 052)
- Operating profit before depreciation, EBITDA, amounted to KSEK -14 353 (-15 532)